CVE-2022-20917

Description

A vulnerability in the Extensible Messaging and Presence Protocol (XMPP) message processing feature of Cisco Jabber could allow an authenticated, remote attacker to manipulate the content of XMPP messages that are used by the affected application. This vulnerability is due to the improper handling of nested XMPP messages within requests that are sent to the Cisco Jabber client software. An attacker could exploit this vulnerability by connecting to an XMPP messaging server and sending crafted XMPP messages to an affected Jabber client. A successful exploit could allow the attacker to manipulate the content of XMPP messages, possibly allowing the attacker to cause the Jabber client application to perform unsafe actions.

Category

4.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.17%
Vendor Advisory cisco.com
Affected: Cisco Cisco Jabber
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2022-20917?
CVE-2022-20917 has been scored as a medium severity vulnerability.
How to fix CVE-2022-20917?
To fix CVE-2022-20917, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-20917 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-20917 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-20917?
CVE-2022-20917 affects Cisco Cisco Jabber.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.